Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsCipla

    Stock analysis is used by traders to make buy and sell call. It’s an approach to make informed decisions while investing in stocks. Stock analysis can be categorised into – fundamental analysis and technical analysis. Fundamental analysis is evaluation of data from sources, including financial records, economic reports, company assets, and market share. Analysts typically study the company’s financial statements – balance sheet, income statement, cash flow statement, and footnotes. These statements are made available to the investors in the form of quarterly earnings, disclosures to stock exchanges in compliance with the Securities and Exchange Board of India (Sebi) norms. In fundamental analysis, the analysts particularly check for a company's core income, income from other sources, profitability, guidance, assets and liabilities and debt ratio among other parameters. The other method, i.e. the technical analysis focuses purely on statistical data. It works on two assumptions; one, the stock price reflects the fundamentals. Second, the study of past and present movement in prices can help determine the future price trends. Technical analysis primarily deals with price, volume, demand and supply factors. This method is effective only when supply and demand forces influence the market. However, when outside factors are involved in a price movement, technical analysis may not be successful. More

    Jump to

    • Check out: Top 10 stocks of the day

      Here's a list of top 10 stocks that are in news today due to fourth quarter earnings, entry into F&O segment and merger deals.

    • Prefer Infosys, Tech Mahindra, HPCL, Sun Pharma: Damania

      Anish Damania, Head-Institutional Equities at IDFC Securities is of the view that one may prefer Infosys, Tech Mahindra, HPCL, IOC, Sun Pharma, Cipla and Strides Arcolab.

    • Buy pharma stocks, uptrend will resume: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one may buy pharma stocks as the uptrend may resume.

    • Buy Lupin, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Lupin.

    • Expect Cipla, Sun Pharma to head lower: Mithil Pradhan

      Mithil Pradhan of Violet Arc Global Managers is of the view that Cipla and Sun Pharma may head lower.

    • Buy Cipla, Sun Pharma at lower levels: Prakash Diwan

      Prakash Diwan of Altamount Capital Management is of the view that one may buy Cipla and Sun Pharma at lower levels.

    • Cipla may test Rs 650-660: Gaurav Mehta

      Gaurav Mehta, VP-Institutional Equities at Ambit Capital is of the view that Cipla may test Rs 650-660.

    • Pick Lupin, Cipla: Kunal Saraogi

      Kunal Saraogi of Equityrush recommends picking Lupin and Cipla.

    • Here are top 10 stocks to focus on April 10

      Here are top 10 stocks to focus on April 10 - Hero MotoCorp, Axis Bank, Bharti Airtel, Idea Cellular, Biocon, Cipla, SBI, Hindalco, IDFC and Max India.

    • Buy Cipla, target Rs 780-820: Kunal Bothra

      Kunal Bothra of LKP Securities recommends buying Cipla with a target of Rs 780-820.

    • Buy Cipla, target Rs 760: Pritesh Mehta

      Pritesh Mehta of IIFL recommends buying Cipla with a target of Rs 760.

    • Buy Cipla, target Rs 752: Sameet Chavan

      Sameet Chavan of Angel Broking recommends buying Cipla with a target of Rs 752.

    • Go long in Sun Pharma, prefer Havells: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends going long in Sun Pharma and prefers Havells India.

    • Buy Cipla, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Cipla as the stock may breakout on the upside.

    • Sell IGL, BHEL; buy Cipla: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends selling Indraprastha Gas and Bharat Heavy Electricals and advises buying Cipla.

    • Buy Dr Reddy's Labs, says Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com is of the view that one can buy Dr Reddy‘s Laboratories.

    • Buy Cipla 720 Call, Century Textiles 580 Call: VK Sharma

      VK Sharma of HDFC Securities is of the view that one can buy Cipla 720 Call and Century Textiles and Industries 580 Call.

    • Go long in UPL, Cipla: Ashish Chaturmohta

      Ashish Chaturmohta of Fortune Equity Broker recommends going long in UPL with a target of Rs 465-470 and Cipla with a target of Rs 770.

    • Buy Cipla, advises Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Cipla as the stock may break on the upside.

    • Go long in Cipla, advises Ashish Chaturmohta

      Ashish Chaturmohta of Fortune Group recommends going long in Cipla with a target of Rs 770-780.

    • Exit Biocon, says Vishal Malkan

      Vishal Malkan of malkansview.com is of the view that one may exit Biocon.

    • Look at pharma stocks: Deven Choksey

      Deven Choksey of KR Choksey Shares And Securities is of the view that one may look at pharma stocks.

    • Buy Cipla, says Rahul Mohindar

      Rahul Mohindar of viratechindia.com recommends buying Cipla as the stock may move towards Rs 780-775.

    • Buy Cipla on dips: Sudarshan Sukhani

      Sudarshan Sukhani of s2analytics.com recommends buying Cipla on dips as the stock may resume its uptrend.

    • Expect 5-6% upside in Cipla, Dr Reddy's: Rahul Mohindar

      Rahul Mohindar of viratechindia.com is of the view that one may see 5-6 percent upside in Cipla and Dr Reddy's Labs.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347